Compare Eli Lilly And Co (LLY) vs Okta, Inc. (OKTA) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

OKTA trades at $150.64, up 0.86% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.96. Revenue growth accelerated to $2.61B in 2025, achieving positive net income of $28M after years of losses, while operating cash flow surged to $750M. Recent news highlights AI-driven cybersecurity demand boosting Okta's identity protection solutions.

Outlook is positive given earnings momentum and sector tailwinds, but high valuation multiples (P/E 108.22) pose risks if growth slows. Analyst consensus is strongly bullish with a $125.78 price target, though competitive pressures and macroeconomic volatility remain key watchpoints for investors.